Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis-Reference-Cited by-同舟云学术

Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis

Published:2019-03 Issue:4 Volume:11 Page:321-333
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Zhang Zhuoya¹,Deng Wei²,Wu Qizhe²,Sun Lingyun¹

Affiliation:

1. Department of Rheumatology & Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China, 210008

2. Pfizer Inc., Beijing, China, 100010

Abstract

There is currently interest in the risk of infections during treatment with new targeted synthetic disease-modifying antirheumatic drugs (DMARDs), specifically the Janus kinase inhibitor tofacitinib. Tofacitinib has been studied extensively in patients with rheumatoid arthritis and has been shown to be effective and generally safe. East Asian countries have a high background rate of tuberculosis (TB) and hepatitis B virus (HBV) infection and the risk of recurrence or reactivation of infections such as TB, HBV and herpes zoster during DMARD therapy is of particular interest in the region. This paper reviews available data on the risk of TB, HBV and herpes zoster infections, including recurrence/reactivation of infections, during treatment with tofacitinib, with a focus on east Asia.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2018-0113

Reference92 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

2. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

3. Overview of safety of non-biologic and biologic DMARDs

4. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers

5. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective study of efficacy of tofacitinib combined with bDMARDs in the treatment of rheumatoid arthritis patients with inadequate response to bDMARDs;International Journal of Rheumatic Diseases;2024-08-28

2. Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study;Frontiers in Medicine;2023-10-18

3. Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective;Dermatology Reports;2023-09-13

4. Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review;Seminars in Arthritis and Rheumatism;2023-02

5. Co-infection of Microsporidia with Mycobacterium tuberculosis in pulmonary patients;2023-01-04